Transforming Growth Factor β Depletion Is the Primary Determinant of Smad Signaling Kinetics

被引:51
|
作者
Clarke, David C. [1 ,2 ]
Brown, Meredith L. [1 ]
Erickson, Richard A. [1 ]
Shi, Yigong [3 ]
Liu, Xuedong [1 ]
机构
[1] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA
[2] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA
[3] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA
基金
美国国家卫生研究院;
关键词
BMP ACTIVITY GRADIENT; TGF-BETA; MORPHOGEN GRADIENT; MEDIATED ENDOCYTOSIS; TUMOR-SUPPRESSOR; XENOPUS CELLS; RECEPTOR; PROTEIN; TRANSDUCTION; ACTIVIN;
D O I
10.1128/MCB.01443-08
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A cell's decision to growth arrest, apoptose, or differentiate in response to transforming growth factor beta (TGF-beta) superfamily ligands depends on the ligand concentration. How cells sense the concentration of extracellular bioavailable TGF-beta remains poorly understood. We therefore undertook a systematic quantitative analysis of how TGF-beta ligand concentration is transduced into downstream phospho-Smad2 kinetics, and we found that the rate of TGF-beta ligand depletion is the principal determinant of Smad signal duration. TGF-beta depletion is caused by two mechanisms: (i) cellular uptake of TGF-beta by a TGF-beta type II receptor-dependent mechanism and (ii) reversible binding of TGF-beta to the cell surface. Our results indicate that cells sense TGF-beta dose by depleting TGF-beta via constitutive TGF-beta type II receptor trafficking processes. Our results also have implications for the role of the TGF-beta type II receptor in disease, as tumor cells harboring TGF-beta type II receptor mutations exhibit impaired TGF-beta depletion, which may contribute to the overproduction of TGF-beta and a consequently poor prognosis in cancer.
引用
收藏
页码:2443 / 2455
页数:13
相关论文
共 50 条
  • [1] Transforming Growth Factor fl Depletion Is the Primary Determinant of Smad Signaling Kinetics (vol 29, pg 2443, 2009)
    Clarke, David C.
    Brown, Meredith L.
    Erickson, Richard A.
    Shi, Yigong
    Liu, Xuedong
    MOLECULAR AND CELLULAR BIOLOGY, 2021, 41 (08)
  • [2] The Smad pathway in transforming growth factor-β signaling
    Haiyan Lin
    Hongmei Wang
    Cheng Zhu
    Science in China Series C: Life Sciences, 2003, 46 : 449 - 463
  • [3] The Smad pathway in transforming growth factor-β signaling
    Lin, HY
    Wang, HM
    Zhu, C
    SCIENCE IN CHINA SERIES C-LIFE SCIENCES, 2003, 46 (05): : 449 - 463
  • [4] The Smad pathway in transforming growth factor-β signaling
    林海燕
    王红梅
    祝诚
    Science in China(Series C:Life Sciences), 2003, (05) : 449 - 463
  • [5] Smad proteins and transforming growth factor-β signaling
    Schiffer, M
    Von Gersdorff, G
    Bitzer, M
    Susztak, K
    Böttinger, EP
    KIDNEY INTERNATIONAL, 2000, 58 : S45 - S52
  • [6] Transforming growth factor-β/Smad signaling function in the aortopathies
    Yuan, Shi-Min
    Wang, Jun
    Hu, Xiao-Nan
    Li, De-Min
    Jing, Hua
    REVISTA BRASILEIRA DE CIRURGIA CARDIOVASCULAR, 2011, 26 (03): : 393 - 403
  • [7] Synthetic triterpenoids enhance transforming growth factor β/Smad signaling
    Suh, N
    Roberts, AB
    Reffey, SB
    Miyazono, K
    Itoh, S
    ten Dijke, P
    Heiss, EH
    Place, AE
    Risingsong, R
    Williams, CR
    Honda, T
    Gribble, GW
    Sporn, MB
    CANCER RESEARCH, 2003, 63 (06) : 1371 - 1376
  • [8] Transforming growth factor-β and breast cancer -: Transforming growth factor-β/SMAD signaling defects and cancer
    Kretzschmar, M
    BREAST CANCER RESEARCH, 2000, 2 (02) : 107 - 115
  • [9] Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
    Marcus Kretzschmar
    Breast Cancer Research, 2
  • [10] Transforming growth factor-betas: smad signaling and roles in physiopathology
    Javelaud, D
    Mauviel, A
    PATHOLOGIE BIOLOGIE, 2004, 52 (01): : 50 - 54